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Abstract 
Since 1950 about 87 000 A-bomb survivors from Hiroshima and Nagasaki 
have been monitored within the framework of the Life Span Study, to 
quantify radiation-induced late effects. In terms of incidence and mortality, a 
statistically significant excess was found for leukemia and solid tumors. In 
another major international effort, neutron and gamma radiation doses were 
estimated, for those survivors (Dosimetry System DS02). Both studies 
combined allow the deduction of risk coefficients that serve as a basis for 
international safety regulations. As an example, current results on all solid 
tumors combined suggest an excess relative risk of 0.47 per Sievert for an 
attained age of 70 years, for those who were exposed at an age of 30 years. 
After exposure to an effective dose of one Sievert the solid tumor mortality 
would thus be about 50% larger than that expected for a similar cohort not 
exposed to any ionizing radiation from the bombs. 
1 Introduction 
After the atomic bomb explosions over Hiroshima and Nagasaki on August 6th and 9th 1945, both 
cities were almost completely destroyed. Those who were hit close to the hypocentres (the hypocentre 
is the vertical projection of the point of explosion (epicentre) to the ground) had almost no chance of 
survival. By end of 1945, about 200 000 inhabitants had died due to the detrimental health effects 
caused by the high doses of ionizing radiation, the blast wave and the heat.  
Acute effects such as epilation, diarrhoea, central nervous system syndrome, etc., however, were 
not the only consequences of the exposure to ionizing radiation: A few years after the explosions, the 
first studies indicated an increase of cataracts and leukemia among the A-bomb survivors [1,2]. In the 
early 1950s a census was initiated by the joint US-Japanese Atomic Bomb Casualty Commission 
which was later replaced by the Radiation Effects Research Foundation (RERF), and about 120 000 
survivors were identified. Based on these individuals, various studies have been made since 1950 to 
investigate any radiation-induced late effects on the health of these survivors. 
There are other cohorts that provide important information on radiation-induced late effects 
such as, for example, (1) the dial painters in the US who incorporated 226,228Rn and showed an excess 
in bone sarcomas [3], (2) the children in Russia, Belarus and the Ukraine who were exposed to 131I and 
showed and excess in thyroid cancer after the Chernobyl accident [4], (3) the uranium miners who 
were exposed to 222Rn and radon progenies and showed an excess in lung cancer mortality [5], (4) 
members of the tuberculosis Massachusetts cohort who were medically exposed to X-ray 
fluoroscopies and showed an excess in breast cancer [6], (5) the Mayak workers in Russia who 
incorporated 239,240Pu and showed an excess of lung cancer [7], (6) the patients who where treated with 
224Ra against tuberculosis and ankylosing spondylitis and who showed an excess in bone sarcomas [8], 
or (7) those who were medically exposed in utero to X-rays in the UK and showed and excess in 
leukemia and solid tumors [9]. However, the cohort of the A-bomb survivors from Hiroshima and 
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Nagasaki is unique for various reasons. Those reasons include, for example, (1) the large number of 
cohort members investigated, (2) the long follow-up period of about 50 years, (3) a composition 
including males and females, children and adults, (4) a whole-body exposure which is more typical for 
radiation protection situations than partial-body exposures typical for many medically exposed 
cohorts, (5) a large dose range from natural to lethal levels, and (6) the fact that the cohort includes an 
internal control group with negligible doses, i.e. those who survived at large distances to the 
hypocentres. In spite of these advantages it is noted, however, that some issues must be kept in mind 
before the results obtained from the A-bomb survivors can be used for general radiation protection: (1) 
The A-bomb survivors were exposed to a high dose rate which is contrary to the situation involving 
low dose rates that are typical for many occupational exposures; (2) The consequences of internal 
exposures cannot be investigated since the survivors were predominantly exposed externally; (3) The 
results obtained on the Japanese cohort can not necessarily be transferred to western-type populations; 
(4) Risk estimates for gamma radiation depend somewhat on the biological effectiveness assumed for 
the neutrons because the survivors were exposed to a mixed neutron and gamma radiation field. 
In general, any study on radiation-induced late-effects requires both, information on disease 
incidence and mortality in the investigated cohort, and information on the doses received by the 
affected individuals during the exposure to radiation. For the A-bomb survivors both are available – 
information on disease incidence and mortality is obtained within the framework of the Life Span 
Study (LSS) project [10-14], while individual doses are given in the dosimetry systems such as DS86 
[15] and, more recently, DS02 [16]. If the observed health data such as the number of deaths due to 
solid cancer are plotted on the y-axis versus dose on the x-axis, any radiation-induced effect would 
appear as a positive correlation (Fig. 1). The slope of a linear correlation can be interpreted as a risk 
coefficient, i.e. as radiation-induced effect per dose of ionizing radiation.  
Below, the LSS and the dosimetry of the A-bomb survivors are described in some detail, 
resulting risk estimates are briefly discussed, and some of the ongoing scientific discussions are 
sketched. Other studies conducted by RERF such as the Adult Health Study (biennial medical 
examinations of about 24 000 A-bomb survivors), the In-utero Study (investigations on about 3300 
individuals who had been exposed in-utero), and the F1-Study (investigations on about 77 000 non-











Fig. 1: Principle of a dose response relationship. The slope of a linear fit through the data 
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2 Y-axis: the data from the life span study 
In a continuous series of reports, RERF has published its findings on the incidence and mortality due 
to leukemia, solid cancer and other diseases, among the members of the LSS cohort. Report 12, for 
example, was based on the follow-up of 86 572 survivors from 1950-1990 [11]. During this period of 
time, 37 670 individuals died due to various reasons including 7578 individuals who died from solid 
cancer, and 249 who died from leukemia. While the number of radiation-induced excess cases was 
quite small compared to the spontaneous cases for solid cancer – in fact, about 334 of the total 7578 
cases corresponding to 4.4% (8.2% among those with a nonzero dose) were attributed to the ionizing 
radiation – it was considerably larger for leukemia (about 87 of the total 249 cases corresponding to 
35% [44% among those with a nonzero dose] were attributed to the radiation). Data given in the most 
recent RERF publication that is based on the follow-up 1950-2000 confirm this trend [14]: about 477 
of the total 10,085 deaths due to solid cancer, and about 93 of the total 296 deaths due to leukemia 
were attributed to the radiation. 
It is interesting to note that for leukemia, most of the radiation-induced excess cases occurred 
during the early phase of the follow-up in the 1950s and 1960s, due to the short latency period of this 
disease (Fig. 2). As mentioned above, extending the follow-up from 1990 to 2000 increased the 
number of observed leukemia cases from 87 to 93, i.e. by about 7%. Any new leukemia case observed 
in the LSS cohort today is thus rather spontaneous than due to the radiation. For solid tumors, however, 
the situation appears to be different: during the early phase of the follow-up the radiation-induced 
fraction of solid tumors was considerably smaller than that for leukemia, but did not decrease 
significantly in the following decades (Fig. 3). Extending the follow-up from 1990 to 2000 increased 
the number of excess solid tumor cases from 334 to 477, i.e. by about 43%. This may highlight why it 
is important to continue this study although more than half a century has already passed since its 
beginning: for solid tumors, a considerable number of radiation-induced cases is still to come. Those 
of the LSS cohort still alive (in fact, about 48% of the survivors were still alive in 1998 [13]) were 
exposed at very young ages. Thus, in the future the study is expected to provide new information on 
the late effects induced by ionizing radiation in children and adolescents. 
 
Fig. 2: Leukemia incidence in Hiroshima and Nagasaki, based on a follow-up 1950–1987 
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 Fig. 3: Solid cancer mortality in Hiroshima and Nagasaki, based on a follow-up 1950–1990 
3 X-axis: the dosimetry of the A-bomb survivors 
While early dose estimates for the gamma and neutron radiation doses in Hiroshima and Nagasaki had 
been performed already in the 1950s and 1960s [17,18], it was in the early 1980s that extensive 
modelling allowed the estimation of organ doses to the survivors on an individual scale. The so-called 
DS86 model included, for example, calculation of the neutron and gamma radiation emitted by the 
exploding bombs (“source terms”), hydrodynamic simulation of the atmosphere disturbed by the 
explosions, coupled neutron and gamma ray transport calculations from the points of explosions 
(“epicentres”) to the ground, quantification of the shielding by Japanese houses and other structures, 
and calculation of the shielding by the human body itself [15]. Figure 4 shows, as an example, the 
location of about 58 000 survivors from Hiroshima at the time of bombing (atb). The color code 
represents DS86 colon doses for these survivors. Figure 4 demonstrates the wide dose range to which 
the LSS cohort was exposed: doses of a few mSv for those who were located beyond about 2500 m 
from the hypocenter on the one hand, and doses up to several Sv for those few who could survive at a 
distance of less than 1000 m from the hypocenter on the other. 
Results of various measurements that had been made in the 1950s and 1960s during test 
explosions on the Nevada Test Site proved the reliability of the DS86 methodology [15]. 
Measurements on environmental samples from Hiroshima containing quartz allowed the retrospective 
determination of the gamma radiation doses from the A-bomb by means of the thermoluminescence 
method. The results indicated somewhat lower experimental doses than calculated by DS86 close to 
the hypocenter, and slightly higher values at distances beyond 1000 m. For example, at a distance of 
about 1400 m from the hypocenter, the experimental data were about 20%-30% higher than those 
calculated [15]. In order to reconstruct the fast neutrons from the Hiroshima A-bomb that were 
responsible for the neutron doses to the survivors, early efforts concentrated on the detection of 32P 
(half-life: 14.2 days) that was produced by fast neutrons in samples that contained sulfur [19,20]. 
Results of these studies showed reasonable agreement with DS86 calculations close to the hypocentre, 
but did not allow firm conclusion to be drawn at distances larger than about 700 m. Since these data 
were the only data on fast neutrons available until recently, an experimental corroboration of the 
neutron doses to the members of the LSS cohort who survived beyond about 1000 m from the 
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hypocenter (see Fig. 4) did not exist. From the 1960s until the mid 1990s, work on neutron fluence 
reconstruction concentrated on those radioisotopes that had been produced by thermal neutrons such 
as 60Co [21], 152Eu [22] and 36Cl [23-25], due to a lack of alternatives. See [26] for a more complete 
list of references. Similar to the results on gamma radiation, most of the experimental results on 
thermal neutrons were somewhat lower close to the hypocentre of Hiroshima, compared to DS86 
calculations. Contrary to the thermoluminescence data, however, the thermal activation measurements 
showed significantly higher results than DS86  approaching factors between 10 and 100 at distances 
beyond 1500 m. Interestingly, the few data available for Nagasaki appeared to support DS86 
calculations even at large distances. A detailed description of the situation as it appeared by 1998 is 
given in [26].   
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Fig. 4: Location of about 58 000 survivors in Hiroshima, at the time of bombing. The color code 
represents dose estimates for the colon obtained from the DS86 model (figure produced by M. 
Chomentowski, Radiobiological Institute, University of Munich, during a stay at RERF 
Hiroshima). 
In the 1990s, the situation prompted major international efforts to improve the A-bomb 
dosimetry. Those efforts included novel approaches for measuring the radioisotope 63Ni produced by 
fast neutrons in copper samples from Hiroshima, additional measurements of radioisotopes produced 
by thermal neutrons, and a complete re-evaluation of all computational aspects of the DS86 dosimetry 
model.  
In a joint Japanese-US-German project, five copper samples could be identified in Hiroshima 
that had been exposed to fast neutrons from the A-bomb. The nickel in those samples was extracted by 
means of a specially developed chemical method [27], and the 63Ni measured at the Munich MLL 
Laboratory by means of accelerator mass spectrometry [28]. The results indicated, within their 
experimental uncertainties, good agreement for four samples that were located at distances beyond 
about 1000 m where people had survived (Fig. 5). Thus, a major discrepancy that had been reported in 
the literature for thermal neutrons was not confirmed for fast neutrons [29].  








500 1000 1500 2000










Fig. 5: Measured 63Ni nuclei per gram copper (symbols) compared to DS86 calculation (solid 
line), as a function of distance from the epicentre 
A joint Japanese-German collaboration was the first to show that new measurements of 36Cl 
produced by thermal neutrons in Hiroshima were in agreement with DS86 calculations at distances 
beyond 1000 m from the hypocentre where previous measurements suggested a major discrepancy 
(Fig. 6) [30-33]. This finding was confirmed by other studies (for example, Ref. [16]). A detailed 
description of the work that was done to improve the dosimetry of the A-bomb survivors and that led 
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Fig. 6: Measured 36Cl/Cl ratios (symbols) compared to DS86 calculation (solid line), as a function 
of distance from the epicentre 
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4 Dose-response relationships obtained from the LSS data 
4.1 Shape of the dose-response curve for solid cancer 
Recently, RERF published the results of a detailed follow-up of the LSS cohort, based on the period 
from 1950 to 1997 [13].  These results are summarized here in terms of the excess relative risk (ERR) 
as a function of weighted colon dose. The ERR is defined as the difference between the number of 
observed solid cancer cases (O) in the cohort, and the number of solid cancer cases expected for the 
cohort (E) if no additional exposure due to A-bomb radiation was present, normalized to this number 
(see Eq. 1). The ERR is a function of dose, sex, age-at-exposure, and age-attained. All data given here 
were calculated for those aged 70 years who were 30 years old atb, and are gender-averaged.  
 ( )/ERR O E E= −   (1) 
where: 
– Ο is the number of cases observed in the exposed cohort, 
– E is the number of cases expected in an identical (hypothetical) cohort not exposed to A-bomb 
radiation. 
The weighted colon dose as used by RERF is the sum of the colon absorbed dose from the 
gamma radiation, and the ten fold colon absorbed dose from the neutrons (Eq. 2). The factor 10 
accounts for the increased relative biological effectiveness (RBE) of the densely-ionizing neutron 
radiation compared to that of the sparsely-ionizing gamma radiation.   
 nDDD ⋅+= 10γ  (2) 
where: 
– D is the weighted absorbed dose to the colon, 
– Dγ is the absorbed dose to the colon due to the gamma radiation, 
– Dn is the absorbed dose to the colon due to the neutrons radiation. 
It is important to note that with the chosen value of 10 for the neutron weighting factor, the 
contribution of the neutrons to the weighted colon dose is relatively small. Based on DS86 or DS02, 
for example, the contribution of the neutrons is less than 10%, at a distance of 1000 m from the 
hypocenter in Hiroshima, and about 1% at a distance of 2000 m. In other words, the major fraction of 
the late effects observed in the LSS is attributed to the gamma radiation if a value of 10 for the neutron 
weighting factor is used. 
The dose-response relationship obtained by RERF for solid tumors is shown in Fig. 7. As a 
major finding is noted that for all solid cancer combined “There is little evidence against a simple 
linear dose response, with the only apparent curvature being a flattening for those with dose estimates 
above 2 Sv that is not statistically significant (p > 0.5)” [13]. Based on a linear dose-response curve, 
an ERR/Sv of 0.47 ± 0.06 is obtained for survivors who are 70 years old, and were exposed at an age 
of 30 years. Until recently, the linear dose-response curve was somewhat surprising since it was not 
observed for leukemia which showed a significant upward curvature [11]. Additionally, based on 
animal experiments, biological experiments and on theoretical considerations, a linear-quadratic rather 
than a pure linear dose-dependence was expected, for the sparsely-ionizing gamma radiation. 
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Fig. 7: Excess relative risk for all solid tumors combined versus weighted colon dose (Eq. 2). The 
linear fit through the data corresponds to a slope of (0.47±0.06)/Sv [13]. 
Preston and coworkers were able to find a statistically significant increase of the ERR with dose 
for those survivors whose doses were below 120 mSv. If the analysis was restricted to those whose 
doses were below 100 mSv, however, a statistically significant slope of the dose-response was not  
observed [13].  
About one year later, RERF published a further report that included an additional three years 
follow-up. While the motivation of this article was primarily to provide a first discussion of the new 
DS02 doses, it is also important for another reason: for the first time a significant upward curvature 
was found in the solid cancer mortality data [14]. This result was independently confirmed by Walsh 
and coworkers who used the earlier follow-up (1950-1997) for their analysis [34]   
4.2 The role of the neutrons 
As has been mentioned earlier, the chosen value of 10 for the RBE of the neutrons implies that most of 
the observed late effects are attributed to the gamma radiation. There are reasons to believe, however, 
that values greater than 10 provide a more realistic description of the biological effectiveness of the 
neutrons. In fact, animal experiments, chromosome aberrations measured in peripheral blood of about 
1800 A-bomb survivors, and recommendations published by the International Commission on 
Radiological Protection (ICRP) [35] would suggest higher values [36–38], as well as a detailed 
analysis of organ-specific risk estimates obtained for solid cancers [39].  
Qualitatively speaking, the use of higher RBE values for the neutrons implies that a larger 
fraction of the observed radiation-induced late effects (e.g. solid cancer or leukemia) is attributed to 
the neutrons. As a consequence, a smaller fraction is attributed to the gamma radiation and thus the 
risk estimates deduced from the LSS cohort for gamma radiation will also become smaller. This effect 
is demonstrated in Figs. 8 and 9. While Figure 8 shows the results of a conventional analysis of the 
solid cancer mortality data (1950-1990) with an assumed RBE value of 10 for the neutrons, Fig. 9 
shows the results based on RBE values of 20, 35, and 50.  
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Fig. 8: Excess relative risk for solid cancer mortality, versus weighted colon dose; a value of 10 is 
used for the neutron RBE [40] 
 
Fig. 9: Excess relative risk for solid cancer mortality, versus weighted colon dose; values of 20, 
35, and 50 are used for the neutron RBE [40]. 
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5 Conclusion 
Data obtained on the A-bomb survivors from Hiroshima and Nagasaki serve as a major basis for 
radiation protection regulations. For more than half a century, considerable efforts have been made to 
quantify the morbidity and mortality of initially about 100 000 individuals. Recently, a major 
international effort came to an end that included re-evaluation of all aspects of A-bomb dosimetry. It 
was concluded that – while previous measurements suggested a significant discrepancy between 
neutron activation measurements and calculations for thermal neutrons – results of more recent 
measurements turned out to be in agreement with these calculations. While current analyses attribute 
most of the observed radiation-induced effects such as leukemia and solid tumors to the gamma 
radiation, more recent analyses suggest the neutrons having contributed considerably to these effects. 
It is expected that a final decision on how to interpret the effect contribution of the neutrons will be 
made in the next couple of years. 
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